Table 6.
HAE attack rate (N = 131) | ||
---|---|---|
IRR (95% CI) | P-value | |
Treatment type | ||
Any LTP (ref: no LTP) | 0.90 (0.84–0.96) | 0.002 |
Baseline covariates | ||
Male sex (ref: female) | 0.94 (0.88–1.00) | 0.043 |
Age at HAE diagnosis (per 10 years) | 1.03 (1.01–1.05) | 0.001 |
HAE attacks before index date (ref: < median) | 1.67 (1.57–1.77) | < 0.001 |
Country of residence (ref: US) | ||
Canada | 0.76 (0.70–0.81) | < 0.001 |
Germany | 0.91 (0.83–1.01) | 0.075 |
Australia | 0.85 (0.78–0.92) | < 0.001 |
UK | 0.86 (0.76–0.97) | 0.014 |
Italy | 0.48 (0.37–0.63) | < 0.001 |
Family history of HAE (ref: no family history) | 1.27 (1.17–1.37) | < 0.001 |
Type 1 HAE (ref: type 2 HAE) | 0.81 (0.75–0.88) | < 0.001 |
Any preexisting comorbidity (ref: no preexisting comorbidity) | 1.13 (1.07–1.20) | < 0.001 |
Previous misdiagnosis (ref: no previous misdiagnosis) | 0.83 (0.75–0.91) | < 0.001 |
CI confidence interval, HAE hereditary angioedema, IRR incidence rate ratio, LTP long-term prophylaxis